FrancophonIA/ELRC3.0 huggingface dataset:
English: Fever ≥ 38°C (≥ 40°C) Any Other Adverse Event Adolescents(9-<18 years)
Romanian: Febră ≥38C (≥40C) Oricare alt eveniment advers Adolescenţi (cu vârsta cuprinsă între 9 şi <18 ani)
English: In the event of an officially declared influenza pandemic due to A/H5N1 virus, persons previously vaccinated with one or two doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics that contained HA antigen derived from a different clade of the same influenza subtype as the influenza pandemic strain may receive a single dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics instead of two doses that are required in previously unvaccinated individuals (see section 5.1).
Romanian: În eventualitatea unei pandemii de gripă oficial declarate, provocată de virusul A/H5N1, la persoanele vaccinate anterior cu una sau două doze de Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics conţinând antigen hemaglutinină (HA) derivată dintr-o variantă diferită din acelaşi subtip de virus gripal ca şi tulpina pandemică de gripă, se poate administra o doză unică de Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics în loc de două doze cum este necesar în cazul persoanelor nevaccinate anterior (vezi pct. 5.1).
English: As with all vaccines, Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics may not fully protect all persons who are vaccinated.
Romanian: La fel ca în cazul tuturor vaccinurilor, este posibil ca Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics să nu protejeze complet toate persoanele vaccinate.
English: Seroprotection rate (95%CI)* Seroconversion rate (95%CI)* Seroconversion factor (95%CI)** * measured by SRH assay ≥ 25 mm2
Romanian: Rata de seroprotecţie (IÎ 95%)* Rata de seroconversie (IÎ 95%)* Factor de seroconversie (IÎ 95%)** * măsurate prin analiza SRH ≥25 mm ** raporturi ale mediilor geometrice ale SRH
English: The following additional adverse events were reported from post-marketing surveillance with Focetria H1N1v (licensed for use from 6 months of age and with a composition that is similar to Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics):
Romanian: S-au raportat următoarele evenimente adverse suplimentare în cadrul supravegherii după punerea pe piaţă, pentru Focetria H1N1v (autorizat pentru administrare începând cu vârsta de 6 luni şi cu o compoziţie similară cu cea a Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics):
English: The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in subjects aged over 60 (limited number of subjects were above 70 years of age) measured by SRH assay assessed in two clinical studies were as follows:
Romanian: Rata de seroprotecţie*, rata de seroconversie* şi factorul de seroconversie** pentru anticorpul anti-HA la H5N1 A/Vietnam/1194/2004 la subiecţi cu vârsta peste 60 ani (un număr limitat de subiecţi avea vârsta peste 70 ani), măsurate prin analiza SRH (single radial haemolysis - hemoliza radială unică), evaluate în două studii clinice, au fost următoarele:
English: The following additional adverse events were reported from post-marketing surveillance with seasonal non-adjuvanted trivalent vaccines in all age groups and an MF59 seasonal adjuvanted trivalent vaccine with a composition similar to Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (surface antigen, inactivated, adjuvanted with MF59C.1) that is licensed for use in elderly subjects 65 years of age and older: Blood and lymphatic system disorders
Romanian: S-au raportat următoarele evenimente adverse suplimentare în cadrul supravegherii după punerea pe piaţă, pentru vaccinuri trivalente sezoniere fără adjuvant, la toate grupele de vârstă şi pentru un vaccin trivalent sezonier cu adjuvant MF59, cu o compoziţie similară celei a Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (antigen de suprafaţă, inactivat, cu adjuvant MF59C.1), autorizat pentru a fi administrat la subiecţi vârstnici cu vârsta de 65 ani şi peste:
English: Like all medicines, Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics can cause side effects, although not everybody gets them.
Romanian: Ca toate medicamentele, Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics poate provoca reacţii adverse, cu toate că nu apar la toate persoanele.
English: Day 43 to Day 1 % SC (95% CI)
Romanian: RMG între Ziua 43 şi Ziua 1 % SC (IÎ 95%) Ziua 43
English: Two doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were administered three weeks apart and a third dose 12 months following the first dose.
Romanian: S-au administrat două doze de Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics la interval de trei săptămâni şi o a treia doză după 12 luni de la prima doză.
English: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a vaccine for use in adults (from 18 to 60 years old).
Romanian: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics este un vaccin destinat utilizării la adulţi (cu vârsta cuprinsă între 18 şi 60 ani) şi vârstnici (cu vârsta peste 60 ani).
English: Common: Brusing of the skin at the injection site, fever and nausea, generally feeling unwell and shivering.
Romanian: Învineţire la locul de injectare, febră şi greaţă, stare generală de rău şi frisoane.
English: In a phase 2 clinical trial (Study V87P3) adult subjects aged 18-65 years primed 6-8 years previously with 2 doses of MF59-adjuvanted H5N3 vaccine /A/Duck/Singapore/97 were administered 2 booster doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics SRH results after the first dose, that mimic prepandemic priming plus single heterologous booster dose, met all CHMP criteria.
Romanian: Într-un studiu clinic de fază 2 (Studiul V87P3), subiecţilor adulţi cu vârsta cuprinsă între 18 - 65 ani primovaccinaţi în urmă cu 6-8 ani cu 2 doze de vaccin H5N3 /A/Duck/Singapore/97 cu adjuvant MF59 li s-au administrat 2 doze de rapel de Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
English: It is estimated that more than 90,000 women have been vaccinated during pregnancy with H1N1v vaccine Focetria which contains the same amount of adjuvant MF59C.1 as. Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics However information on outcomes is currently limited.
Romanian: Se estimează ca au fost vaccinate în timpul sarcinii mai mult de 90000 femei, cu vaccinul vH1N1 Focetria, care conţine aceeaşi cantitate de adjuvant MF59C.1 ca Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
English: The side effects listed below have occurred with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics in clinical studies in adults, including the elderly:
Romanian: Reacţiile adverse prezentate mai jos au apărut în cazul administrării Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics în cadrul studiilor clinice efectuate la adulţi, incluzând vârstnici:
English: Limited data was obtained from women who became pregnant during the course of clinical trials with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics or H1N1v vaccines adjuvanted with MF59C.1.
Romanian: S-au obţinut date limitate provenind de la femeile care au rămas gravide în timpul studiilor clinice cu vaccinurile Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1) sau vH1N1 cu adjuvant MF59C.1.
English: MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from of 57% (50-64) to 79% (68-87) and 55% (48-62) to 58% (47-69) respectively.
Romanian: Rezultatele la testul MN pentru tulpina A/Vietnam/1194/2004 au indicat o rată de seroprotecţie şi o rată de seroconversie între 57% (50-64) până la 79% (68-87) şi respectiv între 55% (48-62) până la 58% (47-69).
English: Gastrointestinal disorders such as nausea, vomiting, abdominal pain and diarrhoea.
Romanian: Tulburări gastro-intestinale Tulburări gastro-intestinale cum sunt greaţa, vărsăturile, durerile abdominale şi diareea.
English: MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from 67% (60-74) to 85% (78-90) and 65% (58-72) to 83% (77-89), respectively.
Romanian: Rezultatele la testul MN pentru tulpina A/Vietnam/1194/2004 au indicat o rată de seroprotecţie şi o rată de seroconversie între 67% (60-74) şi 85% (78-90) şi respectiv între 65% (58-72) şi 83% (77-89).
English: This section describes the clinical experience with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics following a two-dose administration and booster.
Romanian: Această secţiune descrie experienţa clinică pentru Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics după administrarea a două doze şi vaccinarea de rapel.
English: Do not use Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics after the expiry date which is stated on the carton and the label.
Romanian: Nu utilizaţi Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics după data de expirare înscrisă pe cutie şi pe etichetă.
English: Data obtained in adults showed that Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics can be given at the same time as nonadjuvanted seasonal influenza vaccines, with injections made into separate limbs.
Romanian: Datele obţinute în studii la adulţi au arătat că Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics poate fi administrat în acelaşi timp cu vaccinuri gripale sezoniere fără adjuvant, prin injecţii efectuate în membre diferite.
English: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics should be used in accordance with official recommendations.
Romanian: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics trebuie folosit conform recomandărilor oficiale.
English: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics containing HA from A/Vietnam/1194/2004 (homologous to the challenge strain) and an Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics -like H5N1 vaccine, containing hemagglutinin from the A/turkey/Turkey/1/2005-like (heterologous to the challenge strain) were tested.
Romanian: Au fost testate vaccinul Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics, conţinând hemaglutinină [HA] derivată din tulpina A/Vietnam/1194/2004 (omologă faţă de tulpina de expunere) şi un vaccin H5N1 similar Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics, conţinând hemaglutinină derivată din tulpina similară virusului A/turkey/Turkey/1/2005 (heterologă faţă de tulpina de expunere).
English: PSUR submission when Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is used during an influenza pandemic:
Romanian: Depunerea de RPAS-uri când Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics este folosit în timpul unei pandemii de gripă:
English: Therefore the data indicate that Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics may be co-administered with non-adjuvanted seasonal influenza vaccines (with injections made into opposite limbs).
Romanian: Prin urmare, datele indică faptul că Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics poate fi administrat concomitent cu vaccinuri gripale sezoniere fără adjuvant (injecţiile administrându-se în membre diferite).
English: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspension for injection in pre-filled syringe Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Romanian: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspensie injectabilă în seringă preumplută Vaccin gripal prepandemic (H5N1) (antigen de suprafaţă, inactivat, cu adjuvant)
English: * propagated in eggs ** expressed in microgram haemagglutinin.
Romanian: per doză de 0,5 ml * cultivat în ouă ** exprimat în micrograme hemaglutinină.
English: CONDITIONS OF THE MARKETING AUTHORISATION
Romanian: NUMĂRUL AUTORIZAŢIEI DE PUNERE PE PIAŢĂ
English: Name and address of the manufacturers of the biological active substance Novartis Vaccines and Diagnostics S.r.l.
Romanian: Numele şi adresa fabricanţilor substanţei biologic active Novartis Vaccines and Diagnostics S.r.l. Via Fiorentina, 1 - 53100 Siena Italia
English: A single vaccination with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) induced high and rapid serological response in subjects primed 6-8 years previously with two doses of a different surrogate H5N vaccine, having same formulation as Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics but using the strain H5N3.
Romanian: b) Reactivarea memoriei imunitare pe termen lung prin rapel -Administrarea unei doze unice de Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) a indus un răspuns serologic crescut şi rapid la subiecţii primovaccinaţi cu 6-8 ani în urmă cu două doze dintr-un vaccin surogat H5N diferit, cu aceeaşi formulă ca Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics, însă conţinând tulpina H5N3.
English: A third (booster) dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics was administered 6 months onwards after the primary vaccination.
Romanian: S-a administrat o a treia doză (de rapel) de Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics după 6 luni sau mai mult de la vaccinarea primară.
English: For a full list of excipients see section 6.1.
Romanian: 1,175 miligrame per doză de 0,5 ml Pentru lista tuturor excipienţilor, vezi pct. 6.1.
English: Generalised skin reactions including pruritus, urticaria or non-specific rash; angioedema.
Romanian: Afecţiuni cutanate şi ale ţesutului subcutanat Reacţii cutanate generalizate incluzând prurit, urticarie sau erupţie cutanată nespecifică; angioedem.
English: inactivated, adjuvanted) Novartis Vaccines and Diagnostics may be administered but a protective immune response may not be elicited.
Romanian: • Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics poate fi administrat în cazul unor deficienţe ale sistemului imun, însă este posibil să nu se obţină un răspuns imun de protecţie.
English: The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in the adults measured by SRH assay was as follows:
Romanian: Rata de seroprotecţie*, rata de seroconversie* şi factorul de seroconversie** pentru anticorpul anti-HA la H5N1 A/Vietnam/1194/2004 la adulţi, măsurate prin analiza SRH (single radial haemolysis - hemoliza radială unică) au fost următoarele:
English: Toddlers (6-<36 months)
Romanian: Copii mici (cu vârsta cuprinsă între 6 - <36 luni)
English: METHOD AND ROUTE OF ADMINISTRATION To be administered intramuscularly into the deltoid muscle.
Romanian: A se administra intramuscular la nivelul muşchiului deltoid.
English: Study V87P2 Adults booster after 2rd dose
Romanian: Studiul V87P2 Adulţi rapel după a 2-a doză
English: Skin and subcutaneous tissue disorders
Romanian: Tulburări hematologice şi limfatice Trombocitopenie tranzitorie.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 0.5 ml
Romanian: CONŢINUTUL PE MASĂ, VOLUM SAU UNITATEA DE DOZĂ
English: Study V87P13 21 days after 2nd dose N=66
Romanian: Study V87P13 21 zile după a 2-a doză N=66
English: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted).
Romanian: Vaccin gripal prepandemic (H5N1) (antigen de suprafaţă, inactivat, cu adjuvant).
English: Study V87P1 Adults booster after 2nd dose
Romanian: Studiul V87P1 Adulţi rapel după a 2-a doză
English: 1.175 milligrams per 0.5 ml
Romanian: 0,5 ml
English: Study V87P13 21 days after 2nd dose N=143
Romanian: Study V87P13 21 zile după a 2-a doză N=143
English: No post-marketing surveillance data are available following Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics administration.
Romanian: Nu sunt disponibile date de supraveghere după punerea pe piaţă, în urma administrării Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
English: c)
Romanian: A. ETICHETAREA
English: Important information about some of the ingredients of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics
Romanian: Informaţii importante privind unele componente ale Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics
English: In a clinical trial evaluating 4 different vaccination schedules in 240 subjects 18 to 60 years of age, where the second dose was after either 1, 2, 3 or 6 weeks after the first Prepandemic Influenza vaccine
Romanian: Într-un studiu clinic de evaluare a 4 scheme de vaccinare diferite la 240 subiecţi cu vârsta cuprinsă între 18 şi 60 ani, în care cea de-a doua doză a fost administrată la 1, 2, 3 sau 6 săptămâni de la prima doză de Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics, au fost îndeplinite criteriile CHMP, definite prin rezultatele la analiza SRH, la toate grupurile schemelor de vaccinare, după 3 săptămâni de la a 2-a vaccinare.
English: There are no data on co-administration of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics with other vaccines.
Romanian: Nu există date disponibile privind administrarea concomitentă a Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics cu alte vaccinuri.
English: * measured by SRH assay ≥ 25 mm2 ** geometric mean ratios of SRH
Romanian: Factor de seroconversie (IÎ 95%)** * măsurate prin analiza SRH ≥25 mm ** raporturi ale mediilor geometrice ale SRH
English: There are no data regarding the use of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics during breast-feeding.
Romanian: Nu există date cu privire la utilizarea Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics pe perioada alăptării.
English: • if you have had any allergic reaction other than a sudden life-threatening allergic reaction to any ingredient contained in the vaccine, to egg and, chicken protein, ovalbumin, formaldehyde,
Romanian: • dacă aţi prezentat o reacţie alergică, alta decât o reacţie alergică care pune viaţa în pericol, la oricare dintre componentele vaccinului, la ou şi proteine de pui, ovalbumină, formaldehidă, kanamicină şi sulfat de neomicină (antibiotice), sau bromură de cetiltrimetilamoniu (CTAB) (vezi pct. 6 Informaţii suplimentare):
English: Injection 3
Romanian: Suspensie injectabilă.
English: Limited data was obtained from women who became pregnant with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics during the course of clinical trials.
Romanian: S-au obţinut date limitate provenind de la femeile care au rămas gravide în timpul studiilor clinice în care s-a administrat Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
English: Blood and lymphatic system disorders
Romanian: Tulburări hematologice şi limfatice Limfadenopatie.
English: Take special care with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics:
Romanian: Aveţi grijă deosebită când utilizaţi Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics:
English: Up to 50% of the elderly subjects immunised with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were seroprotected at six months.
Romanian: S-a obţinut seroprotecţie la 6 luni la un procent de până la 50% dintre subiecţii vârstnici la care s-a efectuat imunizarea cu Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
English: week later and higher in the groups with longer interval schedules.
Romanian: Magnitudinea răspunsului imun a fost mai scăzută în grupul la care s-a administrat cea de-a 2-a doză 1 săptămână mai târziu şi mai ridicată la grupurile cu scheme de vaccinare bazate pe intervale mai lungi de timp.
English: These side effects may occur with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
Romanian: Aceste reacţii adverse pot să apară şi în cazul administrării Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
English: You should not receive Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics:
Romanian: Nu trebuie să vi se administreze Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics:
English: NAME OF THE MEDICINAL PRODUCT Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspension for injection in pre-filled syringe.
Romanian: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspensie injectabilă în seringă preumplută.
English: The adverse reaction rates reported after either vaccination dose (i.e. 1
Romanian: Frecvenţa reacţiilor adverse raportate după administrarea oricărei doze de vaccinare (adică prima doză, a doua doză sau doza de rapel) au fost similare şi sunt prezentate pe baza următoarei frecvenţe: